Follows adults with severe emphysema treated with a Zephyr lung valve in Japan
Tracks adults with severe emphysema who receive a Zephyr endobronchial valve.
Plain-language title generated from the registry record
Registry title: Zephyr Valve Japan Post-Marketing Surveillance
Key facts
- Where
- Aichi, Gifu, Kanagawa, Kanazawa, Kawasaki, Mie, Nagasaki, Nagoya, Okayama, Osaka, Sapporo, Sendai, Shiga, Tokyo, Toyoake, and Utsunomiya, JapanSee the 17 sites
Where in Japan
- Tosei General HospitalAichi, JapanTaking people
- Gifu Prefectural Medical CenterGifu, JapanTaking people
- Kanagawa Cardio Chest CenterKanagawa, JapanTaking people
- Kanazawa University HospitalKanazawa, JapanTaking people
- St. Marianna University HospitalKawasaki, JapanTaking people
- Matsusaka Civic HospitalMie, JapanTaking people
- Nagasaki University HospitalNagasaki, JapanTaking people
- Nagoya Medical CenterNagoya, JapanTaking people
- Okayama Medical CenterOkayama, JapanTaking people
- Kinki Chuo Chest Medical CenterOsaka, JapanTaking people
- Hokkaido University HospitalSapporo, JapanTaking people
- Tohoku University HospitalSendai, JapanTaking people
- Shiga University HospitalShiga, JapanTaking people
- Tokyo National HospitalTokyo, JapanTaking people
- Fujita Health University HospitalToyoake, JapanTaking people
- Dokkyo University HospitalUtsunomiya, JapanTaking people
- Dokkyo University Hospital (Pulmonary Medicine and Clinical Immunology)Utsunomiya, JapanNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pulmonx Corporation
- Trial code
- NCT06332885
- Record updated
- 17 September 2026
- Original description
This is a multicenter, prospective, observational surveillance enrolling 140 consecutive patients with severe emphysema who are candidates for bronchoscopic lung volume reduction using Zephyr Endobronchial Valve at up to 20 centers across Japan and followed for 12 months.Read full original descriptionShow less
Zephyr Valve Japan Post-Marketing Surveillance
This is a multicenter, prospective, observational surveillance enrolling 140 consecutive patients with severe emphysema who are candidates for bronchoscopic lung volume reduction using Zephyr Endobronchial Valve at up to 20 centers across Japan and followed for 12 months.
Inclusion: Patient is deemed eligible for BLVR using Zephyr Valve, as determined by their treating physician in accordance with Japanese guidelines and approved instruction for use. These include:; Recent respiratory rehabilitation completed within the last 6 months; Not actively smoking (for at least 4 months); TLC ≥ 100%; RV ≥ 175%; FEV1 15-45% post-bronchodilator; 6MWD 100-500 m; mMRC score ≥ 2; No coagulation disorder; No evidence of active respiratory infection; Patient has little to no collateral ventilation (CV-) between the target and ipsilateral lobe as confirmed by Chartis prior to undergoing BLVR; Patient is willing and able to provide informed consent to allow data collection.